Peter Chockley

Natural Killer Cells and synthetic receptors. Assistant Professor at The Ohio State University. opinions=mine

[Peter Chockley @PeterChockley]

First corresponding paper is out! Thank you to @Jorge88382322 and @GiedreKrenciute for the beautiful imaging and brain tumor models, Lindsay Talbot for the stunning HALO assay, and @Kyttaro_Therapy for the mentorship and support. All made possible by @StJude and @StJudeResearch

[Nature Biotechnology @NatureBiotech]

Synapse-tuned CARs enhance immune cell anti-tumor activity https://t.co/paFcoRRbU9

[Waggoner Lab @LabWaggoner]

Antibody S22019F Selectively Recognises KIR2DS1 and Enables Analysis of KIR2DS1+ NK Cells and T Cells @QuirinHammer @karolinskainst
https://t.co/GmCSBC9pv7

[Waggoner Lab @LabWaggoner]

CD39+CD49a+CD103+ NK cells, elicited by epithelial tumor cell exposure, can control solid tumors in mice
https://t.co/TpcooLzLB9 @ScienceTM @JohnSunwooMD @StanfordMed

[Pelotonia Institute for Immuno-Oncology @OhioStatePIIO]

Congrats to Dept. of Molecular Medicine and Therapeutics (MMT), #PIIO member @PeterChockley on being featured in the @AACR Cancer Immunology (CIMM) Junior Investigator Profile! His lab is advancing next-generation #CAR designs & synthetic receptor engineering to enhance #NKcell & #Tcell #antitumor activity.
https://t.co/hOTcyB8xl3

[Malcolm Sim @mjwsim]

The Sim lab has been hard at work and we’re proud to present our first paper.

We developed new methods to study peptide:KIR interactions.

Congratulations to star postdoc Tanusya Murali who led the project.

https://t.co/hN0fbGOSRx

[Pelotonia Institute for Immuno-Oncology @OhioStatePIIO]

🔬 Join us for a live webinar: “Cell Avidity Uncovers Novel KIR:HLA Binding — Predicting Patient Survival Post Stem Cell Transplant” with Dr. @PeterChockley
📅 November 19, 2025 | 4PM (EST)
🔗 Register now: https://t.co/JONaHjTuv0
#CellTherapy #NKcells #KIRHLA #StemCellTransplant #ImmunoOncology

[Peter Chockley @PeterChockley]

@PGTimmune Congrats, Paul!

[Waggoner Lab @LabWaggoner]

Esther Obeng leads a research group focused on myelodysplastic syndromes (MDS) @EmoryMedicine. @JExpMed spoke with Esther about her career, how her patients inform her research, and more
#WomenInSTEM
https://t.co/OidzkpP9ua

[Peter Chockley @PeterChockley]

@CarlKoschmann @chadtough @MottChildren @UMRogelCancer @umichmedicine Which design/target y’all going with??? Super exciting!

[Jennifer Foltz, PhD @FoltzPhd]

The Foltz lab is growing! If you are interested in working on improving NK cell therapies for cancer, consider applying at: https://t.co/DjQaib0nz8 or reaching out to us at https://t.co/uaV443PUQA! @WashUDeptMed @WUSTLImmuno @SitemanCenter

[The Jeremy Chase Crawford Lab @theJCClab]

I’m hiring a sr. bioinformatics research scientist in integrative analysis to perform data analysis and visualization, statistical analysis, experimental design, database development, mathematical modeling, and novel method development. Join the team. https://t.co/xWgc8MLsam

[The Jeremy Chase Crawford Lab @theJCClab]

Come join my lab as a sr. scientist focused on applied integrative biology to develop and implement novel technical approaches for assaying single cell dynamics, high throughput functional screening, and high parameter molecular phenotyping. https://t.co/0YXuvzlePe #NowHiring

[Lindsay Talbot @LindsayJTalbot]

It’s a great day when years of research comes out to the world! Great work from a great team! @StJudeResearch

https://t.co/OQXYrLE2D6

[Peter Chockley @PeterChockley]

@Jeff_Mold Would love to see their cell “definitions”…

[David J Glass MD @davidjglassMD]

RNAseq is commonly performed. We compared N=30 wild-type Bl6 mice to an N=30 heterozygotic knockout with a phenotype, and then downsized. We found you need at least an N= 8-12 to avoid a >50% false positive rate. A 2nd line confirmed the finding.

https://t.co/wwKRUcdKmH

[Fehniger Lab @LabFehniger]

Congrats to @FoltzPhd @Jenn__Tran and the whole team! New insights into the molecular program of memory-like #NKcell @WUSTLmed @WUSTLImmuno @SitemanCenter

https://t.co/zXoylDG8L1

[Peter Chockley @PeterChockley]

@sidichen @YaleGenetics @YaleMed @YaleWestCampus @YaleCancer @YaleData Great to see the final product!

[Nature Biotechnology @NatureBiotech]

In vivo AAV–SB-CRISPR screens of tumor-infiltrating primary NK cells identify genetic checkpoints of CAR-NK therapy https://t.co/itHuSERCCf

[Peter Chockley @PeterChockley]

@jkagan1 Totally agree. 6week vs 8week old mouse can dictate tumor growth or rejection. I rarely accept a 5 week old mouse study as mildly relevant scientifically.

[Peter Chockley @PeterChockley]

@KlebanoffLab @parkerici @MSKCancerCenter Nice story! Any solid tumor plans noting your 2019 JCI paper?

[Stephen Gottschalk @Kyttaro_Therapy]

Join us for The International Conference on Cellular Immunotherapy in Pediatric Oncology (CIPO) at St. Jude in June 2024.

https://t.co/hOw2YsyWzl
@StJude @StJudeResearch @ASTCT @ThePTCTC